Bellevue Group Ag Cytokinetics Inc Transaction History

Bellevue Group Ag

$4.31 Billion
Q1 2025

A detailed history of Bellevue Group Ag transactions in Cytokinetics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 3,741 shares of CYTK stock, worth $116,045. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,741

Previous 10,941 65.81%

Holding current value

$116,045

Previous $514,000 70.82%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$40.19 - $51.12 $289,368 - $368,064	-7,200 Reduced 65.81%	3,741 $150,000
Q3 2024 Nov 14, 2024	SELL	$51.22 - $60.16 $292,875 - $343,994	-5,718 Reduced 34.32%	10,941 $577,000
Q2 2024 Aug 14, 2024	BUY	$47.86 - $75.05 $48,769 - $76,475	1,019 Added 6.52%	16,659 $902,000
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $207,825 - $352,275	-3,260 Reduced 17.25%	15,640 $1.1 Million
Q4 2023 Feb 14, 2024	SELL	$26.88 - $83.49 $489,216 - $1.52 Million	-18,200 Reduced 49.06%	18,900 $1.58 Million
Q2 2023 Aug 14, 2023	SELL	$32.62 - $40.75 $557,802 - $696,825	-17,100 Reduced 31.55%	37,100 $1.21 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $608,090 - $868,870	-17,000 Reduced 23.88%	54,200 $2.48 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $184,992 - $261,696	4,800 Added 7.23%	71,200 $3.45 Million
Q2 2022 Aug 11, 2022	SELL	$33.93 - $48.92 $88,218 - $127,192	-2,600 Reduced 3.77%	66,400 $2.61 Million
Q1 2022 May 13, 2022	BUY	$29.74 - $46.0 $2.05 Million - $3.17 Million	69,000 New	69,000 $2.54 Million

Others Institutions Holding CYTK

# of Institutions

408

Shares Held

127M

Call Options Held

3.66M

Put Options Held

900K

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $2.92B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Cytokinetics Inc Transaction History